文献速递肿瘤 PET/CT放射性药物与辐射防护

靶向PD-L1表达及其动态变化的小分子PET显像放射性示踪剂的合成与临床前评价

Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-23

研究基于苯氧甲基联苯骨架与三羟甲基氨基甲烷末端基团设计并合成[18F]LG-2与[18F]LG-3两种小分子放射性示踪剂,采用点击化学两步法标记。体外细胞摄取实验显示两者与PD-L1特异性结合,B16-F10荷瘤小鼠PET显像中[18F]LG-3肝与肠道摄取较[18F]LG-2降低近50%,且[18F]LG-3 PET信号与PD-L1表达水平呈强线性相关,可评估顺铂与PD-L1抑制剂治疗后PD-L1状态动态变化。

要点

  • [18F]LG-3的放射化学产率为18±5%,[18F]LG-2为15±3%。
  • B16-F10荷瘤小鼠肿瘤摄取[18F]LG-2为6.45±0.38%ID/mL,[18F]LG-3为5.64±0.02%ID/mL。
  • [18F]LG-3在肝脏和肠道的摄取较[18F]LG-2降低近50%。

核心结论

  • 作者认为小分子放射性示踪剂[18F]LG-3是评估PD-L1表达及监测治疗过程中PD-L1状态动态变化的有前景的候选者。

研究设计与样本

  • 研究为临床前研究,设计并合成两种小分子放射性示踪剂[18F]LG-2与[18F]LG-3,基于苯氧甲基联苯骨架并带三羟甲基氨基甲烷末端基团。
  • 放射性标记通过点击化学的两步法实现。
  • 在不同肿瘤细胞中进行细胞摄取实验以确定两种示踪剂对PD-L1的特异性。
  • 通过PET显像研究[18F]LG-2与[18F]LG-3检测体内PD-L1表达及监测化疗和免疫治疗期间PD-L1动态变化的能力。

主要发现

  • [18F]LG-2与[18F]LG-3的放射性标记总放射化学产率分别为15±3%和18±5%。
  • 在不同PD-L1水平的肿瘤细胞中,体外细胞摄取研究显示两种示踪剂与PD-L1特异性结合。
  • B16-F10荷瘤小鼠PET显像显示肿瘤摄取[18F]LG-2为6.45±0.38%ID/mL、[18F]LG-3为5.64±0.02%ID/mL,而[18F]LG-3在肝脏和肠道的摄取较[18F]LG-2降低近50%。
  • [18F]LG-3在A375-hPD-L1、A375-hPD-L1/A375及A375荷瘤小鼠中的PET信号与PD-L1表达水平呈强线性相关。
  • [18F]LG-3 PET显像可准确评估顺铂与PD-L1抑制剂治疗后肿瘤PD-L1状态的动态变化。

关键数值与推荐

  • [18F]LG-2的总放射化学产率为15±3%,[18F]LG-3为18±5%。
  • B16-F10荷瘤小鼠肿瘤摄取[18F]LG-2为6.45±0.38%ID/mL,[18F]LG-3为5.64±0.02%ID/mL。
  • [18F]LG-3在肝脏和肠道的摄取较[18F]LG-2降低近50%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Small molecule-based radiotracers offer several potential advantages in positron emission tomography (PET) imaging, and are therefore a promising approach for non-invasively and accurately monitoring of programmed death ligand 1 (PD-L1) expression in vivo. In this study, two small-molecule radiotracers were developed to assess PD-L1 expression and dynamics during treatments. METHODS: [18F]LG-2 and [18F]LG-3 were designed based on a phenoxymethyl-biphenyl scaffold with a tris-(hydroxymethyl)-aminomethane terminal group. The radiolabeling was achieved by a two-step method through the "click" chemistry. Cellular uptake assays in different tumor cells were performed to determine the specificity of the two tracers to PD-L1. The ability of [18F]LG-2 and [18F]LG-3 to detect PD-L1 expression in vivo as well as to monitor PD-L1 dynamics during chemotherapy and immunotherapy was investigated via PET imaging. RESULTS: The radiolabeling of [18F]LG-2 and [18F]LG-3 was achieved with overall radiochemical yield of 15 ± 3% for [18F]LG-2 and 18 ± 5% for [18F]LG-3. In vitro cell uptake studies in tumor cells with varying PD-L1 levels demonstrated the specific binding of these tracers to PD-L1. PET imaging in mice bearing B16-F10 tumors displayed comparable tumor uptake of 6.45 ± 0.38%ID/mL for [18F]LG-2 and 5.64 ± 0.02%ID/mL for [18F]LG-3, while [18F]LG-3 showed nearly a 50% reduction in uptake in the liver and intestines compared to [18F]LG-2. PET signals of [18F]LG-3 in A375-hPD-L1, A375-hPD-L1/A375 and A375 tumor-bearing mice demonstrated a strong and linear correlation with PD-L1 expression levels. The dynamic of PD-L1 status in tumors after cisplatin and PD-L1 inhibitor treatments were accurately evaluated with [18F]LG-3 PET imaging. CONCLUSION: The small-molecule radiotracer [18F]LG-3 is a promising candidate for evaluating PD-L1 expression and monitoring the dynamic of PD-L1 status during the treatment process.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lv G, Zhang N, Zhu J, et al. Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics. Eur J Nucl Med Mol Imaging. 2025. PMID: 40263208. doi:10.1007/s00259-025-07290-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。